Teledermatology may be disrupting skin care and could be a positive change for patients with skin diseases, according to an article published in The New York Times. Experts explained that prior to 2020, patients with conditions such as hyperpigmentation and alopecia were required to make in-person visits to their dermatologists to receive prescriptions, which could be costly and time-consuming. However, the COVID-19 pandemic saw the widespread introduction of teledermatology, where patients could schedule virtual videoconferencing visits. Some new teledermatology platforms have further allowed patients to shop for prescription-strength drugs at home by simply sending photos of their conditions for validation—after which, drugs can be mailed directly to their homes. One such patient, 43-year-old Fawzia Khan, revealed that she was able to obtain a 60-day retinoid prescription after answering a questionnaire and sending a selfie to one of the teledermatology platforms. The experts noted that the platforms were designed to sell affordable personalized drugs containing a combination of U.S. Food and Drug Administration–approved generic drugs or key regulated drugs and unregulated skin-care ingredients. Although some dermatologists have expressed concern over the new platforms—stating that the formulations of products obtained through them may be detrimental to skin health and emphasizing the importance of visiting a specialist in person to properly treat skin diseases—other dermatologists have been receptive and welcoming of the change. Many dermatologists have opted to consult for the platforms because they offer better pay and incorporate a work-from-home lifestyle. The experts suggested that teledermatology platforms can be improved by providing instructions to patients on taking high-quality photos, offering an overview of drugs’ benefits and side effects, and collecting more detailed medical information and medication history from their users.